Shank-associated RH domain-interacting protein expression is upregulated in entodermal and mesodermal cancer or...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Shank-associated RH domain-interacting protein (SHARPIN) is a key regulator in cellular processes including proliferation, apoptosis, and immune responses.
• SHARPIN's role in malignant tumor initiation and progression is increasingly recognized.
• Understanding SHARPIN's differential expression across various cancer types is crucial for targeted therapies.

Purpose of the Study:

• To investigate SHARPIN expression patterns in 14 distinct cancer types.
• To correlate SHARPIN expression with the embryonic germ layer of origin for each cancer type.
• To determine the subcellular localization of SHARPIN in malignant tumors.

Main Methods:

• Semi-quantitative analysis of SHARPIN expression using immunohistochemistry in tumor and normal tissue samples.
• Evaluation of SHARPIN subcellular localization via immunofluorescence microscopy.
• Analysis of 14 types of human cancers originating from ectoderm, mesoderm, and entoderm.

Main Results:

• SHARPIN expression was significantly upregulated in cancers derived from entodermal and mesodermal germ layers.
• Conversely, SHARPIN expression was downregulated or lost in cancers originating from the ectodermal germ layer.
• SHARPIN predominantly localized to the cytoplasm, with notable exceptions in lung and esophageal cancers showing nuclear localization.

Conclusions:

• SHARPIN exhibits differential expression based on embryonic germ layer origin, acting as an oncogene or anti-oncogene.
• These findings highlight SHARPIN's context-dependent role in tumorigenesis.
• SHARPIN's distinct expression profiles may inform novel diagnostic and therapeutic strategies in oncology.